Market Overview

UPDATE: JP Morgan Raises PT on Pfizer on Takeaways from Meeting with Management

Related PFE
Pfizer's Medivation Receives FDA Approval For Prostate Cancer Drug XTANDI
Johnson & Johnson's Robust Pipeline Supports Its Above-Average Valuation
Why You (And Another Company) Should Buy Gilead - Dividend Sensei (Seeking Alpha)

JP Morgan maintained Pfizer (NYSE: PFE) with an Overweight rating and raised the price target from $31.00 to $32.00.

JP Morgan analyst Chris Schott commented, "Overall, we see several interesting assets in Pfizer's pipeline beyond Eliquis and Xeljanz (most notably PD-991) and believe we are beginning to see results from the company's refocused R&D efforts. In addition, we continue to believe that a larger break-up of Pfizer remains a distinct possibility, particularly if the company's core pharmaceutical portfolio is able to generate sustained growth over time."

Pfizer closed at $27.99 on Tuesday.

Latest Ratings for PFE

Oct 2016JefferiesDowngradesBuyHold
Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!